Table 5.
Treatments used in children with documented SARS-CoV-2 infection
| Author | N | PICU | MV | Noninvasive Ox | Symptomatic alone | Antiviral | Antibiotic | IVIg | CCS | IFN | Other |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lu [10] | 171 | 3 (2%)a | 3 (2%)a | NR | NR | NR | NR | NR | NR | NR | NR |
| Wang [33] | 34 | 0 | 0 | 0 | 0 | 20 (59%)b | 0 | 0 | 0 | 0 | 0 |
| Li [57] | 2 | 0 | 0 | 2 (100%) | 2 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Ji [41] | 2 | 0 | 0 | 0 | 2 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Liu [11] | 6 | 1 (17%) | 1 (17%) | 1 (17%) | 0 | 6 (100%)c | 0 | 1 (17%) | 4 (67%) | 0 | 0 |
| Li [40] | 5 | 0 | 0 | 0 | 0 | 2 (40%) | 2 (40%) | 5 (100%) | 0 | 2 (40%) | 3 (60%)d |
| Sun [31] | 8 | 2 (25%) | 2 (25%) | 6 (75%) | 0 | 8 (100%) | 5 (62%) | 4 (50%) | 5 (62%) | 0 | 1 (12%)e |
| Zheng [32] | 25 | 2 (8%) | 2 (8%) | 0 | 0 | 12 (48%) | 13 (52%) | 2 (8%) | 0 | 12 (48%) | 1 (4%)f |
| Park [43] | 1 | 0 | 0 | 0 | 1 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Liu** [44] | 1 | 0 | 0 | 0 | 0 | 1 (100%)g | 0 | 0 | 1 (100%) | 0 | 0 |
| Cai** [46] | 10 | 0 | 0 | 0 | 5 (50%) | 0 | 5 (50%) | 0 | 0 | 0 | 0 |
| Wang** [36] | 31 | 0 | 0 | 0 | 31 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Zhang** [49] | 2 | 0 | 0 | 0 | 2 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Wei [51] | 9 | 0 | 0 | 0 | 9 (100%) | 0 | 0 | 0 | 0 | 0 | 0 |
| Lou [53] | 3 | 0 | 0 | 0 | 1 (33%) | 0 | 0 | 0 | 0 | 2 (67%) | 0 |
| Xu [37] | 10 | 0 | 0 | 0 | 0 | 0 | 1 (10%) | 1 (10%) | 0 | 10 (100%) | 0 |
| Su [55] | 9 | 0 | 0 | 0 | 0 | 1 (11%)h | 0 | 0 | 0 | 9 (100%) | 0 |
| Pan [58] | 1 | 0 | 0 | NR | NR | NR | NR | NR | NR | NR | NR |
| Chen [62] | 31 | 0 | 0 | 0 | 0 | 3 (10%) | 1 (3%) | 0 | 0 | 30 (97%) | 0 |
| Xing [59] | 3 | 0 | 0 | 0 | 0 | 3 (100%) | 0 | 0 | 0 | 3 (100%) | 3 (100%) |
| Qiu [60] | 36 | 0 | 0 | 6 (17%) | 0 | 14 (39%) | 0 | 0 | 0 | 36 (100%) | 0 |
| Zhang [61] | 34 | 0 | 0 | 3 (10%) | 0 | 28 (82%) | 30 (88%) | 0 | 5 (15%) | 28 (82%) | 0 |
| Shen [71] | 9 | 0 | 0 | 9 (100%) | 0 | 9 (100%) | 5 (56%) | 1 (11%) | 1 (11%) | 0 | 0 |
| Han [72] | 7 | 0 | 0 | 2 (29%) | 4 (57%) | 0 | 0 | 0 | 1 (14%) | 0 | 0 |
| Cui [64] | 1 | 0 | 0 | 0 | 0 | 0 | 1 (100%) | 0 | 0 | 1 (100%) | 1 (100%) |
| Le [69] | 1 | 0 | 0 | 0 | 0 | 0 | 1 (100%) | 0 | 0 | 0 | 0 |
| Li [75] | 40 | 1 (2%) | 1 (2%) | NR | 0 | 20 (50%) | 13 (31%) | 4 (10%) | 3 (7.5%) | 40 (100%) | 0 |
| CDC [76] | 745 | 15 (2%) | 15 (2%) | NR | NR | NR | NR | NR | NR | NR | NR |
| Parri [77] | 100 | 1 (1%) | 1 (1%) | 8 (8%) | NR | NR | NR | NR | NR | NR | NR |
| Tagarro [78] | 41 | 4 (10%) | 1 (3%) | 3 (7%) | NR | NR | NR | NR | NR | NR | NR |
| See [79] | 4 | 0 | 0 | 0 | 3 (75%) | 0 | 1 (25%) | 0 | 0 | 0 | 0 |
| Tan [80] | 10 | 0 | 0 | 0 | 9 (90%) | 0 | 1 (10%) | 0 | 0 | 0 | 0 |
| Zhu [84] | 10 | 0 | 0 | 1 (10%) | 4 (40%) | 5 (50%) | 1 (10%) | 0 | 0 | 4 (40%) | 0 |
| Total | 1402 | 29 | 26 | 41 | 73 | 132 | 80 | 18 | 20 | 177 | 9 |
| % | 2.1 | 1.9 | 9.2i | 21.2j | 38.4 j | 23.3 j | 5.2 j | 5.8 j | 51.5 j | 2.6j |
SARS-CoV-2 severe acute respiratory syndrome–Coronavirus-2, NR not reported, PICU pediatric intensive care unit, MV mechanical ventilation, Noninvasive Ox noninvasive oxygen, IVIg intravenous immunoglobulin, CCS corticosteroids, IFN interferon
aAll with coexisting conditions (hydronephrosis, leukemia, and intussusception); blopinavir and ritonavir; cribavirin 2/6; oseltamivir 6/6; d3/5 montelukast; e1/8 plasmapheresis; f1 also kidney replacement; gribavirin; hribavirin; icalculated on the total of reported treatments (N = 957); jcalculated on the total of reported treatments (N = 1058)
**Studies included in the review by Henry et al. [67]